NXTC Q3 2019 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$7M-447.3% margin

Operating Income

-$10M-612.9% margin

Net Income

-$8M-532.8% margin

EPS (Diluted)

$-4.46

QoQ Revenue Growth

+12.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$524,000

Balance Sheet

Total Assets

$205M

Total Liabilities

$34M

Stockholders' Equity

$171M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$7M	-$5M	-45.9%
Operating Income	-$10M	-$6M	-66.7%
Net Income	-$8M	-$6M	-47.7%